Evidence map›Paper›PMID 29396649›Full record

ArticleMolecular neurobiology2018

Ghrelin Causes a Decline in GABA Release by Reducing Fatty Acid Oxidation in Cortex.

Joan Francesc Mir, Sebastián Zagmutt, Mathieu P Lichtenstein, Judit García-Villoria, Minéia Weber, Ana Gracia, Gemma Fabriàs, Josefina Casas, Miguel López, Núria Casals and 4 more

Open access · hybridAbstract read
In one paragraph

Article in Molecular neurobiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 1 country.

Joan Francesc MirDepartment of Biochemistry and Physiology, Facultat de Farmàcia i Ciències de l'Alimentació and Institut de Biomedicina de la Universitat de Barcelona (IBUB), Universitat de Barcelona, Av. Joan XXIII, 27-30, E-08028, Barcelona, Spain.
Sebastián ZagmuttDepartment of Biochemistry and Physiology, Facultat de Farmàcia i Ciències de l'Alimentació and Institut de Biomedicina de la Universitat de Barcelona (IBUB), Universitat de Barcelona, Av. Joan XXIII, 27-30, E-08028, Barcelona, Spain.
Mathieu P LichtensteinInstitut d'Investigacions Biomèdiques de Barcelona, Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.
Judit García-VilloriaSección de Errores Congénitos del Metabolismo - IBC, Servicio de Bioquímica y Genética Molecular, Hospital Clínic, IDIBAPS, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Barcelona, Spain.
Minéia WeberDepartment of Biochemistry and Physiology, Facultat de Farmàcia i Ciències de l'Alimentació and Institut de Biomedicina de la Universitat de Barcelona (IBUB), Universitat de Barcelona, Av. Joan XXIII, 27-30, E-08028, Barcelona, Spain.
Ana GraciaCentro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, E-28029, Madrid, Spain.
Gemma FabriàsResearch Unit on BioActive Molecules, Department of Biomedicinal Chemistry, Institute of Advanced Chemistry of Catalonia (IQAC)/CSIC, Barcelona, Spain.
Josefina CasasResearch Unit on BioActive Molecules, Department of Biomedicinal Chemistry, Institute of Advanced Chemistry of Catalonia (IQAC)/CSIC, Barcelona, Spain.
Miguel LópezNeurObesity Group, Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, 15782, Santiago de Compostela, Spain.
Núria CasalsCentro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, E-28029, Madrid, Spain.
Antònia RibesSección de Errores Congénitos del Metabolismo - IBC, Servicio de Bioquímica y Genética Molecular, Hospital Clínic, IDIBAPS, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Barcelona, Spain.
Cristina SuñolInstitut d'Investigacions Biomèdiques de Barcelona, Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.
Laura HerreroDepartment of Biochemistry and Physiology, Facultat de Farmàcia i Ciències de l'Alimentació and Institut de Biomedicina de la Universitat de Barcelona (IBUB), Universitat de Barcelona, Av. Joan XXIII, 27-30, E-08028, Barcelona, Spain.
Dolors SerraDepartment of Biochemistry and Physiology, Facultat de Farmàcia i Ciències de l'Alimentació and Institut de Biomedicina de la Universitat de Barcelona (IBUB), Universitat de Barcelona, Av. Joan XXIII, 27-30, E-08028, Barcelona, Spain. dserra@ub.edu.ORCID http://orcid.org/0000-0002-4936-4206
Instituto de Salud Carlos III · ESCentre for Biomedical Network Research on Rare Diseases · ESCentro de Investigación Biomédica en Red de Epidemiología y Salud Pública · ESInstitut de Biomedicina de la Universitat de BarcelonaInstitute of Advanced Chemistry of Catalonia · ESUniversidade de Santiago de Compostela · ESUniversity of the Basque Country · ES

Funding

Agència de Gestió d'Ajuts Universitaris i de Recerca 2014SGR465Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN) CB06/03/0001Consellería de Cultura, Educación e Ordenación Universitaria, Xunta de Galicia 2015-CP079FP7 Ideas: European Research Council FP7/2007-2013 under grant agreement n°281854 - the ObERStressFundació La Marató de TV3 201627-30Ministry of Spain (MINECO) SAF2013-45887-RMinistry of Spain (MINECO) SAF2014-52223-C2-1-RMinistry of Spain (MINECO) SAF2015-71026-R and BFU2015-70454-REDT/Adipoplast
6 · The paper itself

Abstract

Lipid metabolism, specifically fatty acid oxidation (FAO) mediated by carnitine palmitoyltransferase (CPT) 1A, has been described to be an important actor of ghrelin action in hypothalamus. However, it is not known whether CPT1A and FAO mediate the effect of ghrelin on the cortex. Here, we show that ghrelin produces a differential effect on CPT1 activity and γ-aminobutyric acid (GABA) metabolism in the hypothalamus and cortex of mice. In the hypothalamus, ghrelin enhances CPT1A activity while GABA transaminase (GABAT) activity, a key enzyme in GABA shunt metabolism, is unaltered. However, in cortex CPT1A activity and GABAT activity are reduced after ghrelin treatment. Furthermore, in primary cortical neurons, ghrelin reduces GABA release through a CPT1A reduction. By using CPT1A floxed mice, we have observed that genetic ablation of CPT1A recapitulates the effect of ghrelin on GABA release in cortical neurons, inducing reductions in mitochondrial oxygen consumption, cell content of citrate and α-ketoglutarate, and GABA shunt enzyme activity. Taken together, these observations indicate that ghrelin-induced changes in CPT1A activity modulate mitochondrial function, yielding changes in GABA metabolism. This evidence suggests that the action of ghrelin on GABA release is region specific within the brain, providing a basis for differential effects of ghrelin in the central nervous system.

Indexed as

AnimalsCarnitine O-PalmitoyltransferaseCells, CulturedCerebral CortexCitratesCitric Acid CycleFatty Acidsgamma-Aminobutyric AcidGene DeletionGhrelinHypothalamusKetoglutaric AcidsMetabolomeMice, Inbred C57BLNeuronsOxidation-ReductionCarnitine O-PalmitoyltransferaseCitratesFatty Acidsgamma-Aminobutyric AcidGhrelinKetoglutaric AcidsCortical neuronsCPT1AFatty acid oxidationGABAGhrelin

Identifiers

PMID29396649
PMCPMC6096967
OpenAlexW2787570077

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.